WASHINGTON — Chief Justice John Roberts publicly criticized mounting attacks on the Supreme Court, saying such criticism threatens judicial independence. He delivered his remarks at a legal conference, emphasizing the need for institutional trust.
Roberts' defense comes as public confidence in the Court has dropped to 27 percent, a 40-year low, according to Gallup. The scrutiny directly impacts the Court's political capital and its ability to act without perceived partisan influence.
The comments follow renewed calls from Democratic lawmakers to implement court reforms, including mandatory ethics codes and potential legislative efforts to expand the number of justices. These moves aim to curb the Court's power after rulings that reshaped environmental regulations and corporate liability standards.
The U.S. Chamber of Commerce reported $20.1 million in first-quarter 2026 lobbying expenditures, largely focused on protecting business interests from regulatory overreach. The spending highlights the financial sector's stake in judicial stability.
Upcoming cases involve intellectual property rights, antitrust enforcement against tech giants like Alphabet and Meta, and the scope of federal agency power. Decisions in these areas collectively represent billions of dollars in corporate valuations and potential market shifts.
For companies under regulatory oversight, a Court seen as sympathetic to federal agencies offers stability. Conversely, a Court perceived as hostile opens new avenues for legal challenge, benefiting industries seeking deregulation. This creates a win-lose scenario for sectors like pharmaceuticals, where drug pricing and patent challenges are constant, and financial services, where regulatory certainty directly impacts revenue margins.
Lobbying groups representing these industries continue to pour money into influencing judicial appointments and legislative debates on court oversight. The Pharmaceutical Research and Manufacturers of America spent $10.5 million in 2025 advocating for policies favorable to drug patent protection, a key area for Supreme Court review.
